Diana J Lu1, Michael Luu2, Alain Mita3, Kevin Scher3, Stephen L Shiao1, Emi P Yoshida1, Mark P Sittig1, Jon Mallen-St Clair4, Allen S Ho4, Zachary S Zumsteg5. 1. Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. 2. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biostatistics and Bioinformatics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. 3. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. 4. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. 5. Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address: zachary.zumsteg@cshs.org.
Abstract
BACKGROUND: Oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence among older adults. However, the role of human papillomavirus (HPV) in driving this trend and its prognostic significance in this population have not been established. METHODS: The National Cancer Database was queried for patients with OPSCC diagnosed from 2010 to 2015 undergoing either surgery or radiotherapy (RT) with known HPV status. Older adults were defined as those aged 70 years or older. RESULTS: Among 43,427 OPSCC patients, the proportion of HPV-positive OPSCC increased from 45.1% to 63.3% in older adults (P < 0.001). In 19,358 patients meeting the inclusion criteria for survival analyses, HPV positivity was associated with improved survival for older adults undergoing either definitive RT (hazard ratio [HR] = 0.63, 95% confidence interval [CI] 0.55-0.72, P < 0.001) or surgery (HR = 0.37, 95% CI 0.25-0.53, P < 0.001) in multivariable analysis. In propensity score-matched cohorts, 3-year overall survival was 69.1% versus 55.5% (P < 0.001) in older adults with HPV-positive and HPV-negative OPSCC undergoing definitive RT, respectively, and 88.5% versus 69.1% (P = 0.001) for older adults undergoing surgery. Although HPV positivity was associated with improved survival among all age groups receiving RT, the magnitude of the effect diminished with increasing age (interaction P < 0.001). No interaction between age and the impact of HPV status on survival was seen for surgical patients (interaction P = 0.72). CONCLUSIONS: The epidemiologic landscape of HPV-positive OPSCC is evolving, with a dramatic increase in the proportion of HPV-associated OPSCC among patients 70 years or older. HPV remains a powerful predictor of improved survival in elderly patients, but with less pronounced effect on older adults undergoing definitive RT.
BACKGROUND: Oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence among older adults. However, the role of human papillomavirus (HPV) in driving this trend and its prognostic significance in this population have not been established. METHODS: The National Cancer Database was queried for patients with OPSCC diagnosed from 2010 to 2015 undergoing either surgery or radiotherapy (RT) with known HPV status. Older adults were defined as those aged 70 years or older. RESULTS: Among 43,427 OPSCC patients, the proportion of HPV-positive OPSCC increased from 45.1% to 63.3% in older adults (P < 0.001). In 19,358 patients meeting the inclusion criteria for survival analyses, HPV positivity was associated with improved survival for older adults undergoing either definitive RT (hazard ratio [HR] = 0.63, 95% confidence interval [CI] 0.55-0.72, P < 0.001) or surgery (HR = 0.37, 95% CI 0.25-0.53, P < 0.001) in multivariable analysis. In propensity score-matched cohorts, 3-year overall survival was 69.1% versus 55.5% (P < 0.001) in older adults with HPV-positive and HPV-negative OPSCC undergoing definitive RT, respectively, and 88.5% versus 69.1% (P = 0.001) for older adults undergoing surgery. Although HPV positivity was associated with improved survival among all age groups receiving RT, the magnitude of the effect diminished with increasing age (interaction P < 0.001). No interaction between age and the impact of HPV status on survival was seen for surgical patients (interaction P = 0.72). CONCLUSIONS: The epidemiologic landscape of HPV-positive OPSCC is evolving, with a dramatic increase in the proportion of HPV-associated OPSCC among patients 70 years or older. HPV remains a powerful predictor of improved survival in elderly patients, but with less pronounced effect on older adults undergoing definitive RT.
Authors: Joseph E Tota; Ana F Best; Zachary S Zumsteg; Maura L Gillison; Philip S Rosenberg; Anil K Chaturvedi Journal: J Clin Oncol Date: 2019-04-26 Impact factor: 44.544
Authors: V C Sandulache; Y L Lei; L E Heasley; M Chang; C I Amos; E M Sturgis; E Graboyes; E Y Chiao; N Rogus-Pulia; J Lewis; A Madabhushi; M J Frederick; A Sabichi; M Ittmann; W G Yarbrough; C H Chung; R Ferrarotto; Weiyuan Mai; H D Skinner; U Duvvuri; P Gerngross; A G Sikora Journal: Oral Oncol Date: 2019-10-22 Impact factor: 5.337
Authors: Laura Martin-Gomez; William J Fulp; Michael J Schell; Bradley Sirak; Martha Abrahamsen; Kimberly A Isaacs-Soriano; Attila Lorincz; Bruce Wenig; Christine H Chung; Jimmy J Caudell; Anna R Giuliano Journal: Oral Oncol Date: 2019-04-03 Impact factor: 5.337
Authors: Vlad C Sandulache; David C Wilde; Erich M Sturgis; Elizabeth Y Chiao; Andrew G Sikora Journal: Laryngoscope Investig Otolaryngol Date: 2019-10-17
Authors: Alhadi Almangush; Lauri Jouhi; Timo Atula; Caj Haglund; Antti A Mäkitie; Jaana Hagström; Ilmo Leivo Journal: Br J Cancer Date: 2022-01-18 Impact factor: 9.075
Authors: Melissa A Taylor; Jeffery Switchenko; William Stokes; Mihir R Patel; Mark McDonald; Conor Steuer; Ashley Aiken; Jonathan J Beitler; Dong M Shin; Nabil F Saba Journal: Cancer Med Date: 2021-07-20 Impact factor: 4.452